PARPi and Ovarian Cancer Survival
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-80
SponsorShanghai Gynecologic Oncology Group
About this trial
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
Eligibility criteria
Qualifiers
Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
Complete data on first-line treatment and maintenance therapy.
Availability of follow-up data.
Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
Disqualifiers
Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
Missing first-line or follow-up data.
Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
Patients with second relapse.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
6,000 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Shanghai Gynecologic Oncology Group
Lead sponsor
Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China
Collaborator
Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Collaborator
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University
Collaborator
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Collaborator
Source ClinicalTrials.gov